NRXS stock touches 52-week high of $5.67 amid market fluctuations

Published 20/05/2025, 14:32
NRXS stock touches 52-week high of $5.67 amid market fluctuations

In a market that has seen its fair share of volatility, Neuraxis Inc. (NRXS) stock is trading at $2.27, with its 52-week high standing at $3.78. According to InvestingPro analysis, the company shows concerning financial health metrics, with a high Price/Book ratio of 64.4x and rapid cash burn rate. This performance comes as a notable point of interest for investors who have been tracking the company’s performance amidst a challenging economic landscape. The company has experienced a significant downturn over the past year, with a total return of -23.57%. While showing strong recent momentum, Neuraxis remains unprofitable with an EBITDA of -$7M in the last twelve months. For deeper insights into Neuraxis’s financial health and growth potential, investors can access comprehensive analysis through InvestingPro’s detailed research reports, available for over 1,400 US stocks.

In other recent news, Neuraxis Inc. reported a 39% increase in revenue for the first quarter of 2025, reaching $896,000. This growth was primarily driven by a 46% rise in unit sales, despite the company experiencing a 25% increase in operating losses, which totaled $2.3 million. Neuraxis remains debt-free with $2 million in cash on hand. The company has also expanded its insurance coverage to reach 51 million lives and received FDA label expansion for its IV Stem Technology, now covering a broader age range. Furthermore, Neuraxis anticipates accelerated revenue growth and aims for cash flow breakeven, focusing on expanding insurance policy coverage and preparing for the implementation of a Category One CPT Code in early 2026. In terms of market expansion, the company expects guidelines publication by the end of May to further support its efforts. Neuraxis is also in the middle of a soft launch for its RED device, which has received FDA clearance. These developments reflect Neuraxis’ ongoing strategic initiatives to enhance its market presence and financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.